Wet Age-related Macular Degeneration (wAMD) occurs when abnormal blood vessels grow and leak deep within the macula, leading to scarring and irreversible vision loss. This condition affects more than 300 million individuals globally, of which 2.7% are above 55 years of age.

Currently, patients diagnosed with wAMD are prescribed an anti-VEGF (vascular endothelial growth factor), which are delivered through an intravitreal therapy (IVT). These may be given as frequently as monthly intervals. However, patients cannot reliably pick up visual changes in between visits on their own and may not be able to pick up visual deterioration. Instead, frequent clinic visits are required which results in high outpatient workloads.

AVIGA was developed in collaboration with Occutrack Medical Solutions as a home-based monitoring device so wAMD patients can self-monitor and seek treatment when alerted to vision changes

Clinical studies have established consistent results from AVIGA compared to standard clinical tools in patients wAMD patients. Home monitoring can empower patients to better determine disease recurrence to seek timely treatment. The ultimate goal is to promote improvement in patients’ quality of life.